ASH 2021 | Linking poor cytogenetics and outcomes in MDS
Ibrahim Yakoub-Agha
• 12 Dec 2021
Ibrahim Yakoub-Agha, MD, PhD, University of Lille, Lille, France, describes the impact of poor cytogenetics on survival rates post-allogeneic hematopoietic cell transplantation (allo-HCT) in patients with myelodysplastic syndromes (MDS). Previous studies on patients with acute myeloid leukemia (AML) have revealed that specific adverse cytogenetic features such as 17p and 5q abnormalities worsen outcomes post-transplant. However, no subset of complex karyotypes were identified in patients with MDS that significantly affected outcomes. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
